Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054561 · ClinicalTrials.gov registry record · Phase 3
Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00054561: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00054561 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054561, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as isotretinoin use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells. Vitamin E may be able to decrease side effects caused by isotretinoin. It is not yet known whether combining isotretinoin and interferon alfa with vitamin E is more effective than observation in preventing recurrence of head and neck cancer after surgery and/or radiation therapy. PURPOSE: Randomized phase III trial to compare the effectiveness of isotretinoin and interferon alfa combined with vitamin E with that of observation in treating patients who have undergone surgery and/or radiation therapy for stage III or stage IV head and neck cancer.
Interventions
- PROCEDURE adjuvant therapy
- BIOLOGICAL recombinant interferon alfa
- DIETARY_SUPPLEMENT vitamin E
- DRUG isotretinoin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-11-26 |
| Est. Completion | 2009-05-01 |
| Phase | Phase 3 |
What the finished NCT00054561 record still lists
NCT00054561 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which adjuvant therapy is the first listed.
NCT00054561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00054561 about?
NCT00054561 is a clinical study titled "Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy such as isotretinoin use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells. Vitamin E may be able to decrease side effects caused by isotretinoin. It is not yet known whethe...
What is the current status of trial NCT00054561?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-11-26. Estimated completion is 2009-05-01.
What interventions are being tested in trial NCT00054561?
The interventions under investigation include: adjuvant therapy (PROCEDURE), recombinant interferon alfa (BIOLOGICAL), vitamin E (DIETARY_SUPPLEMENT), isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00054561?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI